Medipal HoldingsMAHLY 78 EBITDA Margin % is 2.49% as of Mar. 2026, which is 1% below its 10-year median of 2.51. GuruFocus rates MAHLY with a GF Score™ of 78/100 and a GF Value™ of $16.06 (Fairly Valued). The stock has 1 warning sign investors should review. Among 119 Medical Distribution companies, Medipal Holdings ranks worse than 68.91% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medipal Holdings's EBITDA for the
three
months ended in Mar. 2026 was $142 Mil. Medipal Holdings's Revenue for the
three
months ended in Mar. 2026 was $5,708 Mil. Therefore, Medipal Holdings's EBITDA margin for the quarter that ended in Mar. 2026 was 2.49%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medipal Holdings EBITDA Margin % Related Terms
Medipal Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Medipal Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MAHLY vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Medipal Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medipal Holdings EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medipal Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medipal Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medipal Holdings (MAHLY) has a EBITDA Margin % of 2.49% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medipal Holdings and its competitors. This is near median its historical median of 2.51. Over the past decade, Medipal Holdings' EBITDA Margin % has ranged from 1.99 to 2.76. According to the industry distribution chart, Medipal Holdings ranks #82 out of 119 companies in the Medical Distribution industry, placing it in the top 68.9%.
Is Medipal Holdings' EBITDA Margin % too high?
Medipal Holdings' current EBITDA Margin % of 2.49% is near median its 10-year median of 2.51. Over the past 10 years, this metric has ranged from a low of 1.99 to a high of 2.76. The Medical Distribution industry median EBITDA Margin % is 4.31. Medipal Holdings' value of 2.49% is 42.2% below this industry median. Based on the distribution chart, Medipal Holdings ranks #82 out of 119 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Medipal Holdings has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medipal Holdings' EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Medipal Holdings ranks #82 out of 119 companies for EBITDA Margin %. This places Medipal Holdings in the lower half of its industry. The industry median EBITDA Margin % is 4.31. Medipal Holdings' value of 2.49% is 42.2% below this benchmark. Historically, Medipal Holdings' own EBITDA Margin % has ranged from 1.99 to 2.76 over the past decade. While the company's 10-year median is 2.51 vs. the industry median of 4.31, Medipal Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medipal Holdings's current EBITDA Margin % of 2.49% is 42.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medipal Holdings and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medipal Holdings's current EBITDA Margin % is 2.49%, which is near median its own 10-year median of 2.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medipal Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medipal Holdings (MAHLY) is currently considered Fairly Valued. The stock's GF Value™ is $16.06, compared to a current price of $15.37 — trading 4.3% below its estimated fair value. The current EBITDA Margin % is 2.49%, which is near median its 10-year median of 2.51 and 42.2% below the Medical Distribution industry median of 4.31. Medipal Holdings' overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medipal Holdings (MAHLY), the current EBITDA Margin % is 2.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medipal Holdings (MAHLY) Overvalued in 2026?
Based on GuruFocus' analysis, Medipal Holdings stock appears to be undervalued.
The current stock price of $15.37 is trading 4.3% below its estimated GF Value™ of $16.06.
GuruFocus considers Medipal Holdings to be Fairly Valued.
Key valuation signals for MAHLY:
EBITDA Margin %: 2.49% (near median its 10-year median of 2.51)
GF Value™: $16.06 vs. price of $15.37 (4.3% below fair value)
Industry Position: 42.2% below the Medical Distribution median (#82 of 119)
No single metric tells the full story. See the MAHLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medipal Holdings Corp is engaged in the wholesale distribution of pharmaceuticals, cosmetics, daily necessities, and related products. The company operates through three reportable segments: Wholesale business of medical drugs; Cosmetics, Daily Necessities and OTC Pharmaceuticals Wholesale Business; and Wholesale of animal medicines and food processing ingredients. The Wholesale business of medical drugs segment targets hospitals, clinics, and dispensing pharmacies; the Cosmetics and OTC segment serves drug stores, home centers, convenience stores, and supermarkets; while the Wholesale of animal medicines and food processing ingredients segment supplies veterinary clinics, livestock and fisheries businesses, and food manufacturers.
78GF Score
Get the complete analysis for MAHLY
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAHLY has been successfully added to your 
